Additionally, GLP-1 medications are associated with gastrointestinal side effectsincluding nausea, vomiting, diarrhoea, and constipationwhich can affect nutritional intake and hydration status
Clinical Trial-based Evidence of Benefit Research has shown that GLP-1R agonists play a significant role in reducing the likelihood of MACE, such as MI, cardiovascular death, and stroke [102]
What is included with each Glow Blend Vial
Mol Psychiatry 29 , 25872598 (2024)
Liraglutide Adding liraglutide to intensive behavioral therapy led to greater short-term improvements in eating behaviors, particularly reductions in dietary disinhibition, shape concern, and global eating disorder psychopathology, compared to intensive behavioral therapy alone, with benefits attenuating by week 52 [127]